Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 30.71
UTHR's Cash to Debt is ranked higher than
50% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. UTHR: 30.71 )
Ranked among companies with meaningful Cash to Debt only.
UTHR' s Cash to Debt Range Over the Past 10 Years
Min: 0.69  Med: 9.67 Max: 15951.56
Current: 30.71
0.69
15951.56
Equity to Asset 0.68
UTHR's Equity to Asset is ranked higher than
51% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. UTHR: 0.68 )
Ranked among companies with meaningful Equity to Asset only.
UTHR' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.67 Max: 0.97
Current: 0.68
0.37
0.97
Interest Coverage 93.64
UTHR's Interest Coverage is ranked lower than
80% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 93.64 )
Ranked among companies with meaningful Interest Coverage only.
UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.20 Max: 1479.07
Current: 93.64
2.02
1479.07
F-Score: 7
Z-Score: 8.58
M-Score: -2.51
WACC vs ROIC
15.10%
71.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 51.34
UTHR's Operating margin (%) is ranked higher than
96% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. UTHR: 51.34 )
Ranked among companies with meaningful Operating margin (%) only.
UTHR' s Operating margin (%) Range Over the Past 10 Years
Min: -29.15  Med: 27.54 Max: 46.03
Current: 51.34
-29.15
46.03
Net-margin (%) 47.11
UTHR's Net-margin (%) is ranked higher than
96% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. UTHR: 47.11 )
Ranked among companies with meaningful Net-margin (%) only.
UTHR' s Net-margin (%) Range Over the Past 10 Years
Min: -17.52  Med: 22.13 Max: 56.09
Current: 47.11
-17.52
56.09
ROE (%) 55.05
UTHR's ROE (%) is ranked higher than
98% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. UTHR: 55.05 )
Ranked among companies with meaningful ROE (%) only.
UTHR' s ROE (%) Range Over the Past 10 Years
Min: -11.59  Med: 19.34 Max: 30.84
Current: 55.05
-11.59
30.84
ROA (%) 34.01
UTHR's ROA (%) is ranked higher than
98% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. UTHR: 34.01 )
Ranked among companies with meaningful ROA (%) only.
UTHR' s ROA (%) Range Over the Past 10 Years
Min: -6.75  Med: 12.09 Max: 26.08
Current: 34.01
-6.75
26.08
ROC (Joel Greenblatt) (%) 224.90
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. UTHR: 224.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
UTHR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -43.1  Med: 67.40 Max: 118.55
Current: 224.9
-43.1
118.55
Revenue Growth (3Y)(%) 23.90
UTHR's Revenue Growth (3Y)(%) is ranked higher than
81% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. UTHR: 23.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
UTHR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 37.85 Max: 231.7
Current: 23.9
0
231.7
EBITDA Growth (3Y)(%) 22.80
UTHR's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. UTHR: 22.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
UTHR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56  Med: 8.80 Max: 127.7
Current: 22.8
-56
127.7
EPS Growth (3Y)(%) 19.70
UTHR's EPS Growth (3Y)(%) is ranked higher than
78% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. UTHR: 19.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
UTHR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -50.7  Med: 10.10 Max: 154.4
Current: 19.7
-50.7
154.4
» UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

UTHR Guru Trades in Q1 2015

Lee Ainslie 4,500 sh (New)
Louis Moore Bacon 6,000 sh (New)
Ken Fisher 2,450 sh (New)
Jim Simons 446,500 sh (+141.04%)
First Eagle Investment 372,580 sh (+3.44%)
Joel Greenblatt 291,077 sh (-9.91%)
Paul Tudor Jones 1,800 sh (-25.00%)
John Hussman 25,000 sh (-50.00%)
» More
Q2 2015

UTHR Guru Trades in Q2 2015

Paul Tudor Jones 7,375 sh (+309.72%)
Jim Simons 811,578 sh (+81.76%)
First Eagle Investment 426,880 sh (+14.57%)
John Hussman 25,000 sh (unchged)
Ken Fisher 2,450 sh (unchged)
Louis Moore Bacon Sold Out
Joel Greenblatt 261,125 sh (-10.29%)
Lee Ainslie 3,770 sh (-16.22%)
» More
Q3 2015

UTHR Guru Trades in Q3 2015

Lee Ainslie 9,640 sh (+155.70%)
First Eagle Investment 548,807 sh (+28.56%)
Ken Fisher 2,918 sh (+19.10%)
Joel Greenblatt 301,205 sh (+15.35%)
Jim Simons 866,778 sh (+6.80%)
John Hussman 25,000 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q4 2015

UTHR Guru Trades in Q4 2015

Ken Fisher 3,137 sh (+7.51%)
John Hussman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 9.34
UTHR's P/E(ttm) is ranked higher than
88% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.70 vs. UTHR: 9.34 )
Ranked among companies with meaningful P/E(ttm) only.
UTHR' s P/E(ttm) Range Over the Past 10 Years
Min: 8.83  Med: 25.68 Max: 172.33
Current: 9.34
8.83
172.33
Forward P/E 7.91
UTHR's Forward P/E is ranked higher than
80% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.58 vs. UTHR: 7.91 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 9.34
UTHR's PE(NRI) is ranked higher than
88% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 31.00 vs. UTHR: 9.34 )
Ranked among companies with meaningful PE(NRI) only.
UTHR' s PE(NRI) Range Over the Past 10 Years
Min: 8.84  Med: 25.53 Max: 171.34
Current: 9.34
8.84
171.34
P/B 3.78
UTHR's P/B is ranked lower than
65% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. UTHR: 3.78 )
Ranked among companies with meaningful P/B only.
UTHR' s P/B Range Over the Past 10 Years
Min: 2.01  Med: 4.29 Max: 10.39
Current: 3.78
2.01
10.39
P/S 4.53
UTHR's P/S is ranked higher than
72% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. UTHR: 4.53 )
Ranked among companies with meaningful P/S only.
UTHR' s P/S Range Over the Past 10 Years
Min: 2.83  Med: 6.45 Max: 18.02
Current: 4.53
2.83
18.02
PFCF 14.25
UTHR's PFCF is ranked higher than
73% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 28.77 vs. UTHR: 14.25 )
Ranked among companies with meaningful PFCF only.
UTHR' s PFCF Range Over the Past 10 Years
Min: 9.7  Med: 21.56 Max: 666.33
Current: 14.25
9.7
666.33
POCF 13.63
UTHR's POCF is ranked higher than
75% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 27.35 vs. UTHR: 13.63 )
Ranked among companies with meaningful POCF only.
UTHR' s POCF Range Over the Past 10 Years
Min: 8.25  Med: 19.32 Max: 51.69
Current: 13.63
8.25
51.69
EV-to-EBIT 4.36
UTHR's EV-to-EBIT is ranked higher than
80% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 19.35 vs. UTHR: 4.36 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 20.30 Max: 122
Current: 4.36
-31.2
122
EV-to-EBITDA 4.23
UTHR's EV-to-EBITDA is ranked higher than
80% of the 457 Companies
in the Global Biotechnology industry.

( Industry Median: 16.36 vs. UTHR: 4.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 18.40 Max: 103.2
Current: 4.23
-33.7
103.2
PEG 0.16
UTHR's PEG is ranked higher than
97% of the 91 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. UTHR: 0.16 )
Ranked among companies with meaningful PEG only.
UTHR' s PEG Range Over the Past 10 Years
Min: 0.36  Med: 0.69 Max: 2.41
Current: 0.16
0.36
2.41
Shiller P/E 35.46
UTHR's Shiller P/E is ranked higher than
75% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 52.59 vs. UTHR: 35.46 )
Ranked among companies with meaningful Shiller P/E only.
UTHR' s Shiller P/E Range Over the Past 10 Years
Min: 33.67  Med: 53.54 Max: 543.3
Current: 35.46
33.67
543.3
Current Ratio 2.20
UTHR's Current Ratio is ranked lower than
73% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. UTHR: 2.20 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 6.39 Max: 64.22
Current: 2.2
0.96
64.22
Quick Ratio 2.06
UTHR's Quick Ratio is ranked lower than
69% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. UTHR: 2.06 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 5.83 Max: 64.22
Current: 2.06
0.9
64.22
Days Inventory 443.12
UTHR's Days Inventory is ranked lower than
95% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. UTHR: 443.12 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 285.67
Current: 443.12
118.32
285.67
Days Sales Outstanding 46.59
UTHR's Days Sales Outstanding is ranked higher than
68% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. UTHR: 46.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 44.89 Max: 51.34
Current: 46.59
36.71
51.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 23.81
UTHR's Price/Net Cash is ranked lower than
82% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. UTHR: 23.81 )
Ranked among companies with meaningful Price/Net Cash only.
UTHR' s Price/Net Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.54 Max: 160.03
Current: 23.81
1.51
160.03
Price/Net Current Asset Value 10.18
UTHR's Price/Net Current Asset Value is ranked lower than
68% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. UTHR: 10.18 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
UTHR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.46  Med: 10.68 Max: 5533
Current: 10.18
1.46
5533
Price/Tangible Book 3.79
UTHR's Price/Tangible Book is ranked higher than
50% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. UTHR: 3.79 )
Ranked among companies with meaningful Price/Tangible Book only.
UTHR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.16  Med: 4.01 Max: 18.18
Current: 3.79
1.16
18.18
Price/Projected FCF 1.14
UTHR's Price/Projected FCF is ranked higher than
88% of the 246 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. UTHR: 1.14 )
Ranked among companies with meaningful Price/Projected FCF only.
UTHR' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.25  Med: 4.04 Max: 232.67
Current: 1.14
1.25
232.67
Price/Median PS Value 0.67
UTHR's Price/Median PS Value is ranked higher than
65% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. UTHR: 0.67 )
Ranked among companies with meaningful Price/Median PS Value only.
UTHR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.31 Max: 383.33
Current: 0.67
0.48
383.33
Price/Peter Lynch Fair Value 0.37
UTHR's Price/Peter Lynch Fair Value is ranked higher than
97% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 1.82 vs. UTHR: 0.37 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
UTHR' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.39  Med: 1.32 Max: 5.82
Current: 0.37
0.39
5.82
Price/Graham Number 1.25
UTHR's Price/Graham Number is ranked higher than
67% of the 407 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. UTHR: 1.25 )
Ranked among companies with meaningful Price/Graham Number only.
UTHR' s Price/Graham Number Range Over the Past 10 Years
Min: 1.02  Med: 2.51 Max: 6.17
Current: 1.25
1.02
6.17
Earnings Yield (Greenblatt) (%) 23.09
UTHR's Earnings Yield (Greenblatt) (%) is ranked higher than
94% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. UTHR: 23.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
UTHR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.8  Med: 4.40 Max: 24.48
Current: 23.09
0.8
24.48
Forward Rate of Return (Yacktman) (%) 29.92
UTHR's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 105 Companies
in the Global Biotechnology industry.

( Industry Median: 10.50 vs. UTHR: 29.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
UTHR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -2  Med: 0.80 Max: 56.9
Current: 29.92
-2
56.9

More Statistics

Revenue(Mil) $1407
EPS $ 12.96
Beta1.81
Short Percentage of Float20.66%
52-Week Range $113.20 - 190.29
Shares Outstanding(Mil)45.63

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 1,442 1,703 1,943 1,950
EPS($) 11.75 12.29 15.15 15.21
EPS without NRI($) 11.75 12.29 15.15 15.21

Latest Earnings Webcast

Call starts at Oct 27, 2015 09:00 AM EDT

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UTH.Germany,
United Therapeutics Corp was incorporated in Delaware in June 1996. It is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. Its key therapeutic products and product candidates include: Prostacyclin Analogues, Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product is Remodulin (treprostinil) Injection (Remodulin), which is administered subcutaneously (under the skin) or intravenously (in the vein) for the treatment of pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Phosphodiesterase Type 5 (PDE-5) Inhibitor. PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cyclic GMP) in cells. Cyclic GMP is activated by nitric oxide (NO), a naturally occurring substance in the body that mediates the relaxation of vascular smooth muscle. Monoclonal Antibody (MAb), MAbs act by targeting tumor-associated antigens located on the surfaces of cancer cells to activate a patient's immune system against the cancer cells. The Company is developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute (NCI) of the United States National Institutes of Health (NIH). Glycobiology Antiviral Agents, Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown preclinical indications of efficacy against a broad range of viruses. Cell-Based Therapy,iIn 2011, the Company entered into a license agreement with Pluristem Ltd. (Pluristem) to develop and commercialize its cell-based product known as PLacental eXpanded (PLX) cells for the treatment of PAH. Lung Transplantation, the Company is engaged in developing engineered lungs and lung tissue for transplant into patients suffering from PAH and other lung diseases. The Company competes with a number of approved products including the following: Flolan, Ventavis, Ilomedin , Tracleer, Revatio, Letairis , Veletri, Adempas, Opsumit , generic epoprostenol and generic sildenafil citrate. The Company's operations must comply with extensive laws and regulations in the United States and other countries, including FDA regulations.
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
Cummins and Deckers are Candidates for a January Bounce Nov 20 2015 
Estimated Revenue Up 5% Stock Screen Nov 18 2015 
FDA Approval Of Cancer Drug Catapults United Therapeutics Shares By 2% Mar 11 2015 
Weekly CFO Sells Highlight: United Therapeutics Corp, Williams Companies Inc, Facebook Inc. Oct 12 2014 
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares Dec 27 2013 
John Hussman's Third Quarter Top 5 Nov 07 2013 
Vanguard Health Care Fund Selling Update Oct 30 2013 
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
5 Fast-Growing Small-Cap Stocks to Watch Mar 26 2013 

More From Other Websites
United Therapeutics upgraded by Standpoint Research Feb 10 2016
The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and INSYS... Feb 03 2016
4 Top-Ranked Biotech Stocks on Sale Feb 02 2016
UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Feb 01 2016
United Therapeutics settles patent dispute with Teva Pharmaceuticals Jan 19 2016
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira... Jan 19 2016
UNITED THERAPEUTICS CORP Files SEC form 8-K, Other Events Jan 19 2016
United Therapeutics Corp. – Value Analysis (NASDAQ:UTHR) : January 6, 2016 Jan 06 2016
United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : January 6, 2016 Jan 06 2016
United Therapeutics Corporation To Present At 34th Annual J.P. Morgan Healthcare Conference Jan 06 2016
United Therapeutics Corporation To Present At 34th Annual J.P. Morgan Healthcare Conference Jan 06 2016
8 Biotech Stocks That Should Be in Your Portfolio Right Now Dec 23 2015
UNITED THERAPEUTICS CORP Financials Dec 08 2015
SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent... Dec 07 2015
Top Stock Picks of Multi-Billion Dollar, Healthcare-Focused Fund Palo Alto Investors Dec 01 2015
Hedge Funds Are Selling YPF SA (ADR) (YPF) Dec 01 2015
How Smart Money Is Trading United Therapeutics Corporation (UTHR) Nov 24 2015
United Therapeutics Stock: What is the Social Media Crowd Thinking About UTHR? Nov 11 2015
An Overview of QUAL’s Holdings Nov 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK